ViaCyte wins $6M to advance stem cell treatment for diabetes

02/15/2013 | Genetic Engineering & Biotechnology News

The California Institute for Regenerative Medicine and JDRF, the type 1 diabetes research advocacy group, have agreed to give $3 million each to support ViaCyte's development of a stem cell treatment for type 1 diabetes. ViaCyte plans a regulatory application to conduct proof-of-concept human trials.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT